Immuron (ASX:IMC)
ASX announcement history & article coverage
Transparent by design.
Announcments by Immuron (ASX:IMC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice of Annual General Meeting and Proxy Form
Travelan Phase 2 Study Results Published
Travelan Phase 2 study published with safety confirmed and favourable efficacy trends despite missed primary endpoints
Change in substantial holding
Appendix 4G and Corporate Governance Statement
Annual Report
Immuron reports 6% FY26 sales growth, stronger cash position and clinical partnering progress
Presentation to Coffee Microcaps Conference
PROIBS US Distribution Agreement
Immuron to launch PROIBS® digestive health product in the US via exclusive distribution deal
FY26 Results Presentation
Immuron FY26 results show revenue growth, improved net loss, FDA approval, and strategic reset for profitability
Appendix 4E Preliminary Final Report
Emerging Growth Conference Presentation
Emerging Growth Conference
Investor Presentation
TechKnow Invest Roadshow Presentation
Investor Presentation